Tang Bo, Zhu Heng, Zhou Fan, Zhang Yi
Base for Training Postgradnates, Shengyang Military Command Gerenal Hospital, Liaoning Medical College, Shengyang 110016, Liaoning Province, China; Department of Cell Biology, Institute of Basic Medical Sciences, Academy of Military Medical Sciences, Beijing 100850, China.
Department of Cell Biology, Institute of Basic Medical Sciences, Academy of Military Medical Sciences, Beijing 100850, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Apr;22(2):543-8. doi: 10.7534/j.issn.1009-2137.2014.02.052.
Acute graft-versus-host disease (aGVHD) is the major complication associated with allogeneic hematopoietic stem cell transplantation (allo-HSCT) and the major cause of morbidity and mortality following allo-HSCT. Diagnosis of aGVHD is typically based on clinical symptoms and confirmed by biopsy. Once aGVHD has occurrence, the steroids should be the first choice of treatment. However, if the treatment with steroids failed, the prognosis would be poor. In recent years, the novel strategies for the treatment of aGVHD have been developed. In this article, the clinical features, pathogenesis and novel strategies, including mAb treatment, physical and cell therapies are briefly summarized.
急性移植物抗宿主病（aGVHD）是异基因造血干细胞移植（allo-HSCT）相关的主要并发症，也是allo-HSCT后发病和死亡的主要原因。aGVHD的诊断通常基于临床症状，并通过活检确诊。一旦发生aGVHD，类固醇应为首选治疗药物。然而，如果类固醇治疗失败，预后将很差。近年来，已开发出治疗aGVHD的新策略。本文简要总结了aGVHD的临床特征、发病机制及新策略，包括单克隆抗体治疗、物理治疗和细胞治疗。
